Overview
SCIENTIFIC SCORE
Possibly Effective
Based on 16 Researches
7.4
USERS' SCORE
Good
Based on 23 Reviews
8.2
Supplement Facts
Serving Size: 1 Softgel
Amount Per Serving
%DV
Vitamin A (from Retinyl Palmitate and Fish Liver Oil)
7,500 mcg
833%
Top Medical Research Studies
9
We focused on how all-trans retinoic acid (ATRA), a form of vitamin A, helps combat resistance in epithelial ovarian cancer (EOC) when combined with standard platinum-based chemotherapy, such as cisplatin.
Our findings indicate that ATRA effectively reduced PARP inhibitor resistance in EOC cells, both in lab settings and in animal models.
Additionally, using ATRA along with ongoing treatment improved survival rates in EOC-bearing mice. This suggests that ATRA could be an important part of future therapies for enhancing the effectiveness of existing treatments.
Our findings indicate that ATRA effectively reduced PARP inhibitor resistance in EOC cells, both in lab settings and in animal models.
Additionally, using ATRA along with ongoing treatment improved survival rates in EOC-bearing mice. This suggests that ATRA could be an important part of future therapies for enhancing the effectiveness of existing treatments.
Read More
8
Retinoic acid enhances glioma treatment
We investigated how retinoic acid (RA), a derivative of vitamin A, could influence cancer treatment, particularly in glioma, a type of brain tumor. Previous attempts to use RA as a therapeutic option were inconclusive, so we aimed to explore its effects alongside extracellular ATP (eATP) to harness their combined potential.
Our experiments examined two human glioma cell lines, M059K and M059J, to see how they responded to RA-based differentiation. Notably, this process led to changes in the expression of a receptor called P2X7 and reduced the activity of enzymes that break down nucleotides. These modifications contributed to a significant decrease in cell proliferation and migration abilities, as well as an increased sensitivity to the effects of eATP.
Specifically, we found that in the presence of eATP, cell viability decreased by up to 40% in RA-treated M059K cells and 20% in M059J cells. Migration capabilities of the cells were reduced by as much as 60% when exposed to a specific concentration of ATP, showing that the P2X7 receptor plays a major role in mediating these effects.
Our observations suggest that combining retinoic acid with eATP can have anti-cancer benefits by influencing purinergic signaling pathways in glioma cells. This points to the need for further exploration of P2X7 receptor variants as potential therapeutic targets for treating glioma.
Our experiments examined two human glioma cell lines, M059K and M059J, to see how they responded to RA-based differentiation. Notably, this process led to changes in the expression of a receptor called P2X7 and reduced the activity of enzymes that break down nucleotides. These modifications contributed to a significant decrease in cell proliferation and migration abilities, as well as an increased sensitivity to the effects of eATP.
Specifically, we found that in the presence of eATP, cell viability decreased by up to 40% in RA-treated M059K cells and 20% in M059J cells. Migration capabilities of the cells were reduced by as much as 60% when exposed to a specific concentration of ATP, showing that the P2X7 receptor plays a major role in mediating these effects.
Our observations suggest that combining retinoic acid with eATP can have anti-cancer benefits by influencing purinergic signaling pathways in glioma cells. This points to the need for further exploration of P2X7 receptor variants as potential therapeutic targets for treating glioma.
Read More
8
We investigated the role of Vitamin A, specifically retinoic acid, in enhancing the immune response of γδ T cells in patients with nasopharyngeal carcinoma (NPC). By analyzing blood samples, we observed that Vitamin A can reduce markers of immune exhaustion that are often elevated in cancer.
Importantly, our study showed that vitamin supplementation improved the antitumor activity of T cells by decreasing a specific protein linked to immune fatigue. This suggests that Vitamin A could be a valuable ally in cancer therapies, potentially opening doors for more effective immunotherapy options.
Importantly, our study showed that vitamin supplementation improved the antitumor activity of T cells by decreasing a specific protein linked to immune fatigue. This suggests that Vitamin A could be a valuable ally in cancer therapies, potentially opening doors for more effective immunotherapy options.
Read More
Most Useful Reviews
9
Improved gastritis
56 people found this helpful
The required amount of Vitamin A varies significantly depending on individual circumstances. Those with dry eye, asthma, gastrointestinal issues, or a family history of cancer may require more. I gradually increased my intake to 100,000 units for a year, which cleared my persistent red sore gastritis, eliminating the need for medication.
Read More
9
Healed cystitis
52 people found this helpful
Vitamin A has been fantastic for me. Despite a family history of cancer, I was cautious about overdosing, so I started at 25,000 and moved to 50,000. My cystitis improved, corns softened, and irregular bleeding stopped. If I can heal without surgery, I will continue striving for 75,000 daily!
Read More
9
Improved eyesight
13 people found this helpful
Following a high-protein, low-sugar diet and taking Vitamin A has improved my eyesight, and my wife's presbyopia has resolved. We take these supplements to prevent cancer due to a familial history, which is particularly important for our health.
Read More
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 16 Researches
7.4
- All Researches
9.5
We constructed a zebrafish model to explore how a unique version of the PML-RARA protein, linked to acute promyelocytic leukemia (APL), might respond to treatment with all-trans retinoic acid (ATRA). This model allowed us to examine whether ATRA, a derivative of vitamin A, could be effective for patients with atypical APL characteristics.
In our findings, we observed that the response of the new PML-RARA isoform to ATRA treatment was similar to classical isoforms seen in the condition. We also found that ATRA worked well in this model, leading to favorable results for the treated patient, who reached complete remission shortly after starting therapy with ATRA and arsenic trioxide (ATO).
These results highlight the promising potential of vitamin A derivatives in cancer treatment, especially in various forms of APL. It's encouraging to see that ATRA can lead to substantial recovery, further supporting its use in clinical settings alongside other therapies.
In our findings, we observed that the response of the new PML-RARA isoform to ATRA treatment was similar to classical isoforms seen in the condition. We also found that ATRA worked well in this model, leading to favorable results for the treated patient, who reached complete remission shortly after starting therapy with ATRA and arsenic trioxide (ATO).
These results highlight the promising potential of vitamin A derivatives in cancer treatment, especially in various forms of APL. It's encouraging to see that ATRA can lead to substantial recovery, further supporting its use in clinical settings alongside other therapies.
Read More
9.5
Promising APL treatment outcomes observed
We aimed to understand the effectiveness of a combination treatment involving all-trans retinoic acid (ATRA), arsenic trioxide (ATO), and gemtuzumab ozogamicin (GO) for patients with acute promyelocytic leukemia (APL). This was a phase 2 trial involving newly diagnosed APL patients, where ATRA and ATO were used to induce remission.
The results were promising, as we observed a complete remission rate of 93.8% among the participants. Furthermore, 97.1% of those who achieved remission had no measurable residual disease, indicating a strong initial response to the treatment regimen.
Over a median follow-up of about 62 months, the 5-year survival rates were also impressive, with event-free survival at 92.4%, disease-free survival at 93.6%, and overall survival at 93.1%. We noted some side effects, including elevated liver enzymes and infections, but there were no severe complications like veno-occlusive disease.
While the study highlights the benefits of ATRA in this combination treatment, we must clarify that we cannot specifically isolate the effect of vitamin A, as it was part of a broader therapeutic approach. Nonetheless, the combination of ATRA with other agents showed significant success in treating APL, reinforcing the importance of multifaceted cancer therapies.
The results were promising, as we observed a complete remission rate of 93.8% among the participants. Furthermore, 97.1% of those who achieved remission had no measurable residual disease, indicating a strong initial response to the treatment regimen.
Over a median follow-up of about 62 months, the 5-year survival rates were also impressive, with event-free survival at 92.4%, disease-free survival at 93.6%, and overall survival at 93.1%. We noted some side effects, including elevated liver enzymes and infections, but there were no severe complications like veno-occlusive disease.
While the study highlights the benefits of ATRA in this combination treatment, we must clarify that we cannot specifically isolate the effect of vitamin A, as it was part of a broader therapeutic approach. Nonetheless, the combination of ATRA with other agents showed significant success in treating APL, reinforcing the importance of multifaceted cancer therapies.
Read More
9
We observed that certain types of Acute Myeloid Leukemia (AML), specifically acute erythroleukemia and acute megakaryocytic leukemia, have a concerningly short median survival and limited effective treatment options. Our exploration focused on understanding the role of the transcription factor GATA1, which is crucial for the survival of cells in these leukemia subtypes. Remarkably, we discovered that a compound known as Fenretinide (or 4-HPR), a synthetic derivative of vitamin A, can target and induce loss of GATA1 in these AML cells.
As we delved into the study, we found that treating M6 AML cells with low concentrations of 4-HPR led to significant cytotoxic effects, akin to reducing GATA1 levels through genetic methods. This indicates that 4-HPR could act similar to a targeted therapy, directly impacting the survival of these cancer cells. Further, we were encouraged to see that 4-HPR not only performed effectively on its own but also enhanced the effectiveness of existing treatments like Azacytidine and Venetoclax, which typically struggle against drug resistance.
Our findings suggest that 4-HPR might represent a promising therapeutic avenue for patients with M6 and M7 AML, paving the way for its potential inclusion as a standard treatment option in the near future. The safety profile of Fenretinide, established through numerous clinical trials, further strengthens the case for its application in the combat against these aggressive forms of leukemia.
As we delved into the study, we found that treating M6 AML cells with low concentrations of 4-HPR led to significant cytotoxic effects, akin to reducing GATA1 levels through genetic methods. This indicates that 4-HPR could act similar to a targeted therapy, directly impacting the survival of these cancer cells. Further, we were encouraged to see that 4-HPR not only performed effectively on its own but also enhanced the effectiveness of existing treatments like Azacytidine and Venetoclax, which typically struggle against drug resistance.
Our findings suggest that 4-HPR might represent a promising therapeutic avenue for patients with M6 and M7 AML, paving the way for its potential inclusion as a standard treatment option in the near future. The safety profile of Fenretinide, established through numerous clinical trials, further strengthens the case for its application in the combat against these aggressive forms of leukemia.
Read More
9
This study delved into the effects of a compound called Acyclic Retinoid, which is derived from vitamin A, on lung cancer and its resistance to a common chemotherapy drug, cisplatin. We explored how Acyclic Retinoid could impact key signaling pathways that contribute to the growth and spread of non-small cell lung cancer (NSCLC), a prevalent and deadly form of the disease. Our focus was on how ACR affected the signals associated with the cancer progression, particularly the EGFR/AKT pathway, which is often overactive in lung cancer situations.
We treated various types of lung cells—including standard cancer cell lines and those resistant to cisplatin—with ACR, both alone and alongside cisplatin. By examining cell viability, apoptosis (the process of programmed cell death), and changes in important cellular signals, we gathered insightful data on the potential of this treatment. The results were promising; ACR inhibited the EGFR/AKT signaling pathway and showed an ability to improve the effectiveness of cisplatin against NSCLC and its resistant variants.
Overall, we observed that Acyclic Retinoid may hold significant promise as a therapeutic strategy for lung cancer, particularly for those patients who have developed resistance to traditional treatments. Its capability to enhance the effects of existing chemotherapy options could lead to better outcomes for patients battling this challenging disease.
We treated various types of lung cells—including standard cancer cell lines and those resistant to cisplatin—with ACR, both alone and alongside cisplatin. By examining cell viability, apoptosis (the process of programmed cell death), and changes in important cellular signals, we gathered insightful data on the potential of this treatment. The results were promising; ACR inhibited the EGFR/AKT signaling pathway and showed an ability to improve the effectiveness of cisplatin against NSCLC and its resistant variants.
Overall, we observed that Acyclic Retinoid may hold significant promise as a therapeutic strategy for lung cancer, particularly for those patients who have developed resistance to traditional treatments. Its capability to enhance the effects of existing chemotherapy options could lead to better outcomes for patients battling this challenging disease.
Read More
9
Vitamin A combined with SM effective
We explored the potential of all-trans retinoic acid (ATRA), a derivative of vitamin A, in treating melanoma. In our study, we combined ATRA with sphingomyelin (SM) to see if this pairing could enhance its effectiveness against aggressive melanoma cells.
We focused on an in vitro model using B16F10 melanoma cells and assessed how well this combination could promote cell death and stop the cells from growing. Our results highlighted that the combination of 123 μM of ATRA with 136 μM of SM was particularly effective, leading to a dramatic reduction in cell proliferation and significant apoptotic cell death.
This combination not only increased the expression of key genes that promote cell death, but it also caused a halt in the cell cycle, preventing cancer cells from continuing to grow. Moreover, our findings suggest that using ATRA alongside SM may provide a promising avenue for melanoma treatment while minimizing harm to normal, healthy cells.
We focused on an in vitro model using B16F10 melanoma cells and assessed how well this combination could promote cell death and stop the cells from growing. Our results highlighted that the combination of 123 μM of ATRA with 136 μM of SM was particularly effective, leading to a dramatic reduction in cell proliferation and significant apoptotic cell death.
This combination not only increased the expression of key genes that promote cell death, but it also caused a halt in the cell cycle, preventing cancer cells from continuing to grow. Moreover, our findings suggest that using ATRA alongside SM may provide a promising avenue for melanoma treatment while minimizing harm to normal, healthy cells.
Read More
User Reviews
USERS' SCORE
Good
Based on 23 Reviews
8.2
- All Reviews
- Positive Reviews
- Negative Reviews
9
Improved gastritis
56 people found this helpful
The required amount of Vitamin A varies significantly depending on individual circumstances. Those with dry eye, asthma, gastrointestinal issues, or a family history of cancer may require more. I gradually increased my intake to 100,000 units for a year, which cleared my persistent red sore gastritis, eliminating the need for medication.
Read More
9
Healed cystitis
52 people found this helpful
Vitamin A has been fantastic for me. Despite a family history of cancer, I was cautious about overdosing, so I started at 25,000 and moved to 50,000. My cystitis improved, corns softened, and irregular bleeding stopped. If I can heal without surgery, I will continue striving for 75,000 daily!
Read More
9
Improved eyesight
13 people found this helpful
Following a high-protein, low-sugar diet and taking Vitamin A has improved my eyesight, and my wife's presbyopia has resolved. We take these supplements to prevent cancer due to a familial history, which is particularly important for our health.
Read More
10
Improved stability
7 people found this helpful
I was advised by my doctor to take 225,000 IU of vitamin A daily due to a positive cancer marker. Since then, my numbers have stabilised. I've also been taking Vitamin C (5,000 IU) and Vitamin D (10,000 IU). Despite overdose concerns, I’ve experienced no issues after three years. My doctor believes high levels of vitamins A, C, and D can mitigate severe outcomes from both COVID-19 and cancer. I'm satisfied with the quality of NOW products.
Read More
9
Cancer protection
1 people found this helpful
Vitamin A is vital for protecting against viral infections and improving mucous membranes, vital for both cancer treatment and general health. It accelerates wound healing and supports cell metabolism. I was advised to use it for psoriasis; the dosage and quality seem advantageous.
Read More
Frequently Asked Questions
8
Reduced symptoms
5 people found this helpful
This vitamin A product is excellent for my son and me. We take 25,000 IU daily, with a month’s break, from September to May. It has alleviated dry skin and acne, conditions which many suffer from without realising their cause may be vitamin A deficiency. I noted improvements within a week, and I find stronger immunity, skin health, and overall wellness beneficial in managing cancer risks.
7.5
Normal tumour markers
13 people found this helpful
After five years of taking Vitamin A, my cancer tumour markers returned to normal. I initially took very high doses (225,000 IU) to combat infections. Following my doctor's guidance and adopting an organic diet helped restore my health, and I now take 75,000 IU daily.
10
Improved stability
7 people found this helpful
I was advised by my doctor to take 225,000 IU of vitamin A daily due to a positive cancer marker. Since then, my numbers have stabilised. I've also been taking Vitamin C (5,000 IU) and Vitamin D (10,000 IU). Despite overdose concerns, I’ve experienced no issues after three years. My doctor believes high levels of vitamins A, C, and D can mitigate severe outcomes from both COVID-19 and cancer. I'm satisfied with the quality of NOW products.
9
Improved gastritis
56 people found this helpful
The required amount of Vitamin A varies significantly depending on individual circumstances. Those with dry eye, asthma, gastrointestinal issues, or a family history of cancer may require more. I gradually increased my intake to 100,000 units for a year, which cleared my persistent red sore gastritis, eliminating the need for medication.
7.5
Eczema relief
43 people found this helpful
My hand eczema improved significantly after I began taking 50,000 IU of Vitamin A daily, which I initially hesitated to do due to overdose concerns. Before, I relied on corticosteroids, but now I no longer experience the itchiness that plagued me at night.
7.5
Family protection
9 people found this helpful
I use Vitamin A as part of my megavitamin therapy. Since starting it over a year ago, I haven’t caught a cold. I ensure to take it with protein to avoid overdosing and believe it helps protect against cancer risks that my family faces.
6
No side effects
4 people found this helpful
For cancer prevention, my doctor recommended 75,000 IU daily. I've been in good health and continue taking Vitamin C. While it feels like a high amount, I have experienced no side effects after two years. I recommend discussing any high-dose treatments with your healthcare provider.
9
Healed cystitis
52 people found this helpful
Vitamin A has been fantastic for me. Despite a family history of cancer, I was cautious about overdosing, so I started at 25,000 and moved to 50,000. My cystitis improved, corns softened, and irregular bleeding stopped. If I can heal without surgery, I will continue striving for 75,000 daily!
9.5
Promising APL treatment outcomes observed
We aimed to understand the effectiveness of a combination treatment involving all-trans retinoic acid (ATRA), arsenic trioxide (ATO), and gemtuzumab ozogamicin (GO) for patients with acute promyelocytic leukemia (APL). This was a phase 2 trial involving newly diagnosed APL patients, where ATRA and ATO were used to induce remission.
The results were promising, as we observed a complete remission rate of 93.8% among the participants. Furthermore, 97.1% of those who achieved remission had no measurable residual disease, indicating a strong initial response to the treatment regimen.
Over a median follow-up of about 62 months, the 5-year survival rates were also impressive, with event-free survival at 92.4%, disease-free survival at 93.6%, and overall survival at 93.1%. We noted some side effects, including elevated liver enzymes and infections, but there were no severe complications like veno-occlusive disease.
While the study highlights the benefits of ATRA in this combination treatment, we must clarify that we cannot specifically isolate the effect of vitamin A, as it was part of a broader therapeutic approach. Nonetheless, the combination of ATRA with other agents showed significant success in treating APL, reinforcing the importance of multifaceted cancer therapies.
The results were promising, as we observed a complete remission rate of 93.8% among the participants. Furthermore, 97.1% of those who achieved remission had no measurable residual disease, indicating a strong initial response to the treatment regimen.
Over a median follow-up of about 62 months, the 5-year survival rates were also impressive, with event-free survival at 92.4%, disease-free survival at 93.6%, and overall survival at 93.1%. We noted some side effects, including elevated liver enzymes and infections, but there were no severe complications like veno-occlusive disease.
While the study highlights the benefits of ATRA in this combination treatment, we must clarify that we cannot specifically isolate the effect of vitamin A, as it was part of a broader therapeutic approach. Nonetheless, the combination of ATRA with other agents showed significant success in treating APL, reinforcing the importance of multifaceted cancer therapies.
9
This study delved into the effects of a compound called Acyclic Retinoid, which is derived from vitamin A, on lung cancer and its resistance to a common chemotherapy drug, cisplatin. We explored how Acyclic Retinoid could impact key signaling pathways that contribute to the growth and spread of non-small cell lung cancer (NSCLC), a prevalent and deadly form of the disease. Our focus was on how ACR affected the signals associated with the cancer progression, particularly the EGFR/AKT pathway, which is often overactive in lung cancer situations.
We treated various types of lung cells—including standard cancer cell lines and those resistant to cisplatin—with ACR, both alone and alongside cisplatin. By examining cell viability, apoptosis (the process of programmed cell death), and changes in important cellular signals, we gathered insightful data on the potential of this treatment. The results were promising; ACR inhibited the EGFR/AKT signaling pathway and showed an ability to improve the effectiveness of cisplatin against NSCLC and its resistant variants.
Overall, we observed that Acyclic Retinoid may hold significant promise as a therapeutic strategy for lung cancer, particularly for those patients who have developed resistance to traditional treatments. Its capability to enhance the effects of existing chemotherapy options could lead to better outcomes for patients battling this challenging disease.
We treated various types of lung cells—including standard cancer cell lines and those resistant to cisplatin—with ACR, both alone and alongside cisplatin. By examining cell viability, apoptosis (the process of programmed cell death), and changes in important cellular signals, we gathered insightful data on the potential of this treatment. The results were promising; ACR inhibited the EGFR/AKT signaling pathway and showed an ability to improve the effectiveness of cisplatin against NSCLC and its resistant variants.
Overall, we observed that Acyclic Retinoid may hold significant promise as a therapeutic strategy for lung cancer, particularly for those patients who have developed resistance to traditional treatments. Its capability to enhance the effects of existing chemotherapy options could lead to better outcomes for patients battling this challenging disease.
8
We investigated the role of Vitamin A, specifically retinoic acid, in enhancing the immune response of γδ T cells in patients with nasopharyngeal carcinoma (NPC). By analyzing blood samples, we observed that Vitamin A can reduce markers of immune exhaustion that are often elevated in cancer.
Importantly, our study showed that vitamin supplementation improved the antitumor activity of T cells by decreasing a specific protein linked to immune fatigue. This suggests that Vitamin A could be a valuable ally in cancer therapies, potentially opening doors for more effective immunotherapy options.
Importantly, our study showed that vitamin supplementation improved the antitumor activity of T cells by decreasing a specific protein linked to immune fatigue. This suggests that Vitamin A could be a valuable ally in cancer therapies, potentially opening doors for more effective immunotherapy options.
5
We explored the potential benefits of vitamin A as a complementary treatment for pancreatic cancer, particularly in pancreatic ductal adenocarcinoma (PDAC), which remains one of the deadliest forms of cancer. Our investigation revealed that vitamin A, alongside vitamins C and D, showed promising signs of inhibiting tumor cell growth in laboratory settings and preclinical models.
The effectiveness of vitamin A seems to be linked to its ability to activate specific nuclear receptors that influence gene activity. This could make tumor cells more susceptible to other therapies, potentially improving treatment outcomes.
However, while initial findings are encouraging, there's a strong need for further research in clinical settings to better understand how vitamin A works on a cellular level and to determine the most effective ways to incorporate it into standard care. With PDAC patients facing limited treatment options and short survival times, exploring such avenues could be vital in enhancing patient care and outcomes.
The effectiveness of vitamin A seems to be linked to its ability to activate specific nuclear receptors that influence gene activity. This could make tumor cells more susceptible to other therapies, potentially improving treatment outcomes.
However, while initial findings are encouraging, there's a strong need for further research in clinical settings to better understand how vitamin A works on a cellular level and to determine the most effective ways to incorporate it into standard care. With PDAC patients facing limited treatment options and short survival times, exploring such avenues could be vital in enhancing patient care and outcomes.
References
- Mere Del Aguila E, Tang XH, Gudas LJ. Retinoic acid receptor-β deletion in a model of early pancreatic ductal adenocarcinoma (PDAC) tumorigenesis. Am J Cancer Res. 2025;15:127. doi:10.62347/XFOT8509
- Raza Y, Yu G, Chiappone SB, Liu S, Luberto C. Fenretinide targets GATA1 to induce cytotoxicity in GATA1 positive Acute Erythroid and Acute Megakaryoblastic Leukemic cells. bioRxiv. 2025. doi:10.1101/2025.01.19.633759
- Motoyama M, Shigefuku R, Tanaka N, Nishizawa M, Oshio K, et al. Acyclic Retinoid Inhibits the EGFR/AKT Signaling Pathway and Cancels Cisplatin-resistant Cell Characteristics. Anticancer Res. 2025;45:433. doi:10.21873/anticanres.17432
- Balasundaram N, Narayanan MA, Antony LSA, Kumar SR, Anandan S. Effectiveness of Fenugreek as an Adjuvant in the Management of Oral Potentially Malignant Disorders: A Randomized Controlled Trial. J Contemp Dent Pract. 2024;25:921. doi:10.5005/jp-journals-10024-3773
- Piotrowsky A, Burkard M, Schmieder H, Venturelli S, Renner O, et al. The therapeutic potential of vitamins A, C, and D in pancreatic cancer. Heliyon. 2025;11:e41598. doi:10.1016/j.heliyon.2024.e41598
- Ye Y, Zhao Z, Mo W, Liu W, Wu L, et al. Zebrafish modeling of atypical PML-RARA isoform from acute promyelocytic leukemia patient and its implications for clinical treatment. Ann Hematol. 2025;104:171. doi:10.1007/s00277-024-06169-x
- Kocher HM, Sasieni P, Corrie P, McNamara MG, Sarker D, et al. Study protocol: multi-centre, randomised controlled clinical trial exploring stromal targeting in locally advanced pancreatic cancer; STARPAC2. BMC Cancer. 2025;25:106. doi:10.1186/s12885-024-13333-z
- Işlek Köklü Z, Şanverdi EL, Karadağ B, Üçişik MH, Taşkan E, et al. Combinational therapy of all-trans retinoic acid (ATRA) and sphingomyelin induces apoptosis and cell cycle arrest in B16F10 melanoma cancer cells. Turk J Biol. 2024;48:401. doi:10.55730/1300-0152.2715
- Aydin D, Öner Ç, Aslan Öztürk S, Çolak E. Short-term effects of retinoic acid on the proliferation of SH-SY5Y cells via mitophagy and apoptosis. Cell Mol Biol (Noisy-le-grand). 2024;70:64. doi:10.14715/cmb/2024.70.11.9
- Sánchez-Mendoza SE, de Deus-Wagatsuma VM, do Nascimento MC, Lima K, Machado-Neto JA, et al. All-trans retinoic acid potentiates cell death induced by quizartinib in acute myeloid leukemia with FLT3-ITD mutations. Ann Hematol. 2024;103:5405. doi:10.1007/s00277-024-06089-w
- Kanai M, Shinagawa A, Ota M, Virgona N, Yano T. Resveratrol Can Differentiate Human Melanoma Stem-like Cells from Spheroids Treated With All-trans Retinoic Acid. Anticancer Res. 2024;44:5283. doi:10.21873/anticanres.17356
- Szymczak B, Pegoraro A, De Marchi E, Grignolo M, Maciejewski B, et al. Retinoic acid-induced alterations enhance eATP-mediated anti-cancer effects in glioma cells: Implications for P2X7 receptor variants as key players. Biochim Biophys Acta Mol Basis Dis. 2025;1871:167611. doi:10.1016/j.bbadis.2024.167611
- Jen WY, Marvin-Peek J, Kantarjian HM, Alvarado Y, Borthakur G, et al. Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia. Cancer. 2025;131:e35662. doi:10.1002/cncr.35662
- Liu G, Quan Q, Pan L, Duan H, Zhang G, et al. Retinoic acid enhances γδ T cell cytotoxicity in nasopharyngeal carcinoma by reversing immune exhaustion. Cell Commun Signal. 2025;23:156. doi:10.1186/s12964-025-02161-8
- Nurseta T, Indrawan IWA, Gunawan DA, Pramudia Wardani KR. Effects Atra on MMP-9 Activity and Integrin Expression in Choriocarcinoma Culture Cell Line Bewo (ATCC CCL-98). Asian Pac J Cancer Prev. 2025;26:1027. doi:10.31557/APJCP.2025.26.3.1027
- Mei B, Li J, Wang D, Feng L, Huang J, et al. All-trans Retinoic Acid Sensitizes Epithelial Ovarian Cancer to PARP Inhibition after Exposure to Cisplatin. Mol Cancer Ther. 2025;24:453. doi:10.1158/1535-7163.MCT-24-0140
